Christopher Ho joined Caris Life Sciences in 2025 and leads revenue cycle operations and policy strategy.
Mr. Ho brings more than 25 years of experience in genetics, molecular diagnostics and oncology, with extensive expertise in reimbursement, payer strategy and operational leadership. Before joining Caris, he served as Senior Vice President of Payer Strategy and Revenue Cycle Management at Myriad Genetics, where he led a team of over 300 professionals responsible for prior authorization, billing, appeals, coverage, contracting and coding for molecular diagnostic products. During his tenure, he also held leadership roles in managed markets, customer service and sales, driving successful reimbursement strategies and market access for innovative products.
Mr. Ho earned his Master of Science in Medical Genetics from the University of Wisconsin–Madison and a Bachelor of Arts in Interdisciplinary Studies with a focus on Medical Ethics from the University of Minnesota.